CN Patent

CN110662557A — 免疫原性组合物、用途和治疗方法

Assigned to GlaxoSmithKline Biologicals SA · Expires 2020-01-07 · 6y expired

What this patent protects

本发明涉及免疫原性组合物，其包含来自流感嗜血杆菌的免疫原性多肽或其免疫原性片段和/或来自卡他莫拉氏菌的免疫原性多肽或其免疫原性片段，所述免疫原性组合物用于治疗或预防受试者中的由细菌感染导致的慢性阻塞性肺病的急性恶化(AECOPD)的复发。

USPTO Abstract

本发明涉及免疫原性组合物，其包含来自流感嗜血杆菌的免疫原性多肽或其免疫原性片段和/或来自卡他莫拉氏菌的免疫原性多肽或其免疫原性片段，所述免疫原性组合物用于治疗或预防受试者中的由细菌感染导致的慢性阻塞性肺病的急性恶化(AECOPD)的复发。

Drugs covered by this patent

umeclidinium-bromide (UMECLIDINIUM BROMIDE)

Patent Metadata

Patent number: CN110662557A
Jurisdiction: CN
Classification: —
Expires: 2020-01-07
Drug substance claim: No
Drug product claim: No
Assignee: GlaxoSmithKline Biologicals SA
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.